Search results
Results from the WOW.Com Content Network
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Psychological therapies for dementia are starting to gain some momentum. [ when? ] Improved clinical assessment in early stages of Alzheimer's disease and other forms of dementia , increased cognitive stimulation of the elderly, and the prescription of drugs to slow cognitive decline have resulted in increased detection in the early stages.
Assistive technology (AT) is a term for assistive, adaptive, and rehabilitative devices for people with disabilities and the elderly. Disabled people often have difficulty performing activities of daily living (ADLs) independently, or even with assistance.
Similar to the NINCDS-ADRDA Alzheimer's Criteria are the DSM-IV-TR criteria published by the American Psychiatric Association. [3] At the same time the advances in functional neuroimaging techniques such as PET or SPECT that have already proven their utility to differentiate Alzheimer's disease from other possible causes, [4] have led to proposals of revision of the NINCDS-ADRDA criteria that ...
The hallmark symptom of LATE is a progressive memory loss that predominantly affects short-term and episodic memory. [1] This impairment is often severe enough to interfere with daily functioning and usually remains the chief neurologic deficit, unlike other types of dementia in which non-memory cognitive domains and behavioral changes might be noted earlier or more prominently. [1]
A transcutaneous electrical nerve stimulation (TENS or TNS) is a device that produces mild electric current to stimulate the nerves for therapeutic purposes.TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation, but the term is often used with a more restrictive intent, namely, to describe the kind of pulses produced by portable ...
The idea of a collaboration between public institutions and private pharmaceutical companies to fund a large biomarker project to study AD and to speed up progress toward effective treatments for the disease was conceived at the beginning of the millennium by Neil S. Buckholz at the National Institute on Aging (NIA) and Dr. William Potter, at Eli Lilly and Company. [1]
Since dementia patients have trouble communicating their needs, this can be frustrating for the nurse. Nurses may have a hard time forming relationships with their dementia patients because of the communication barrier. How the dementia patient feels is based on their social interactions, and they may feel neglected because of this barrier. [35]